Hikma appoints Douglas Hurt as Director

London, 30 April 2020 – Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (Hikma) announces the appointment of Douglas Hurt as an independent non-executive director effective 1 May 2020. Over the course of 2020, Douglas will assume responsibility for chairing the Audit Committee.

Press Release Corporate 30 April 2020

text 1

“I am very pleased that Douglas will be joining Hikma's Board.  He brings a wealth of experience, particularly in relation to operational and financial management, reporting, risk and leadership of audit committees.' said Said Darwazah, Executive Chairman. 'Over the course of 2020, we will undertake the transition of the Audit Committee chair to Douglas and the role of Senior Independent Director to Pat Butler.”

During his executive career, Douglas served as Finance Director of IMI plc, the global engineering group, from 2006 to 2015. Prior to this, he held a number of senior finance and general management positions at GlaxoSmithKline plc, which he joined in 1983, previously having worked at Price Waterhouse. His career has included several years working in the US as the Chief Financial Officer and significant experience in European businesses as an Operational and Regional Managing Director.

Douglas is the Senior Independent Director and Chairman of the Audit Committee at Vesuvius PLC and Countryside Properties PLC.  He is a non-executive director and Chairman of the Audit Committee of the British Standards Institution.   Douglas served as Senior Independent Director and Chairman of the Audit Committee of Tate & Lyle plc until July 2019.

Douglas is a Chartered Accountant and holds an MA(Hons) in Economics from Cambridge University.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.